Opinion|Videos|November 20, 2026

Real-World Outcomes and Treatment Management With CAR T-Cell Therapy in CLL

Dr. Jennifer J. Huang summarizes a multicenter US real-world study evaluating lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Jennifer J. Huang summarizes a multicenter US real-world study evaluating lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Unlike clinical trials with strict eligibility criteria, the study assessed outcomes in patients treated in routine clinical practice. The complete response rate was in the mid-40% range, higher than that reported with liso-cel monotherapy in the TRANSCEND CLL004 study and similar to the rate observed in the liso-cel plus ibrutinib cohort. Dr. Huang notes that many patients received pirtobrutinib as their most recent treatment and that continuing the prior therapy through the period between leukapheresis and lymphodepletion was associated with better outcomes than discontinuing it during that interval. Dr. Mazyar Shadman also discusses evolving CAR T-cell care requirements, including greater flexibility in post-treatment monitoring and discharge timing. He emphasizes that earlier return home may be possible for selected patients when clinically appropriate and when the patient, treating team, and receiving physician are comfortable with the plan.


Related to this article